Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Overactive bladder syndrome complicates life for many women. 60-70% of women report
improvement with treatment but the antikolinergic treatment is often limited by the adverse
events, for example dry mouth, obstipation and urinary retention. Mirabegron is a
b3-adrenoreceptor agonist which induces detrusor relaxation. Earlier studies has demonstrated
similar efficacy comparing Mirabegron with antimuscarinics but a significant reduction of
adverse events. The aim of the present study is to survey cardiovascular adverse events with
Mirabegron treatment in a general population suffering from overactive bladder syndrome.